Navigation Links
Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
Date:4/11/2013

ements, among others, relating to our future capital requirements and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and unc
'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
2. Pharmacyclics, Inc. Prices Public Offering of Common Stock
3. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
4. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
5. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
6. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
7. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
8. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
9. New survey finds women who suffer from migraines want a better understanding of migraine triggers
10. First sales of DIFICLIRâ„¢ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
11. Cardinal Health Foundation, The Ohio State University Launch Fourth Toolkit to Help Reduce Abuse of Prescription Drugs on College Campuses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... R.I. , July 10, 2014 CVS Caremark ... board of directors has approved a quarterly dividend of $0.275 ... dividend is payable on August 1, 2014, to holders of ... CVS Caremark is dedicated to helping people ... pharmacy company in the United States . ...
(Date:1/15/2014)... Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... used on patients in order to treat dental impairments, ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a ... with abnormal auto-immune responses and inflammation, has selected the ... large scale GMP clinical and pre-commercial supplies of A-623, ... of autoimmune diseases. "Establishing a rapid and ...
... Reportlinker.com announces that a new market research report ... 2010 Pharmaceuticals Research Review ... slowdown has accentuated the fault lines already dividing ... large pharma companies, coupled with the patent expiration ...
Cached Medicine Technology:Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Anthera's Investigational Novel Peptibody Agent 2Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Anthera's Investigational Novel Peptibody Agent 3Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Anthera's Investigational Novel Peptibody Agent 4Reportlinker Adds 2010 Pharmaceuticals Research Review 2Reportlinker Adds 2010 Pharmaceuticals Research Review 3Reportlinker Adds 2010 Pharmaceuticals Research Review 4Reportlinker Adds 2010 Pharmaceuticals Research Review 5Reportlinker Adds 2010 Pharmaceuticals Research Review 6Reportlinker Adds 2010 Pharmaceuticals Research Review 7Reportlinker Adds 2010 Pharmaceuticals Research Review 8Reportlinker Adds 2010 Pharmaceuticals Research Review 9Reportlinker Adds 2010 Pharmaceuticals Research Review 10Reportlinker Adds 2010 Pharmaceuticals Research Review 11Reportlinker Adds 2010 Pharmaceuticals Research Review 12Reportlinker Adds 2010 Pharmaceuticals Research Review 13Reportlinker Adds 2010 Pharmaceuticals Research Review 14
(Date:7/10/2014)... Thompson HealthDay Reporter THURSDAY, ... wars that break out regularly between outspoken celebrities or loudmouth ... own relationship, a new study suggests. High amounts of ... if the couple is in a long-term relationship, according to ... In turn, that friction can lead to cheating and breakups, ...
(Date:7/10/2014)... responders felt better prepared to respond to an active ... a new study in the journal Prehospital and ... specifically examine the EMS provider comfort level with respect ... yet been neutralized or working with law enforcement personnel ... High School shooting, the Virginia Tech campus shooting, the ...
(Date:7/10/2014)... amount of alcoholic beverages consumed, even for light-to-moderate ... risk of coronary heart disease, lower body mass ... new multi-center study published in The BMJ ... Medicine at the University of Pennsylvania. The latest ... that consuming light-to-moderate amounts of alcohol (0.6-0.8 fluid ...
(Date:7/10/2014)... The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. , ... unique model developed at UH to enhance care for ... demonstrated need for high health care utilization. ...
(Date:7/10/2014)... imaging far outweigh the risks when children receive The ... Radiation Dose. However, overuse and misuse of imaging change ... collaborative effort to ensure a national protocol is put ... Journal of Patient Safety , calls for the American ... Commission, and the Centers for Medicare & Medicaid Services ...
Breaking Medicine News(10 mins):Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3Health News:Active shooter training increases comfort level of emergency responders 2Health News:New study shows drinking alcohol provides no heart health benefit 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2
... Analysis of a drug regimen approved by the F.D.A. ... (bevacizumab added to the standard chemotherapy regimen carboplatin and paclitaxel) ... received this regimen did not have improved survival compared to ... alone, according to a study in the April 18 issue ...
... The Prospective Surveillance Model, an innovative new model of breast ... American Cancer Society,s journal, Cancer released on April ... by women with breast cancer and offers hope for an ... through rehabilitation and exercise. APTA members Nicole ...
... (Toronto) People with an opioid addiction had the highest risk ... drugs, according to a new study by the Centre for ... on opioids, the risk of death was 5.71 times higher ... gender and race. Those with methamphetamine use disorders were next ...
... plays an integral role in physical health dates back to ... referred to as the founder of medicine, wrote "natural ... University of Missouri team has tapped into the science and ... award-winning program. Called "Taking Care of You: Body-Mind-Spirit," ...
... undergoing chemoradiation therapy (CRT) for head and neck cancer, ... short-term improvement in swallowing function; however, there were no ... and controls at nine or 12 months following treatment, ... Archives of Otolaryngology Head & Neck Surgery ...
... MONDAY, April 16 (HealthDay News) -- Tattoos and body piercings ... in western societies, but a new study in France found ... than their peers. In the study, researchers asked ... they left bars and other drinking establishments. The readings showed ...
Cached Medicine News:Health News:Study examines drug regimen for the treatment of non-small cell lung cancer among older patients 2Health News:Study examines drug regimen for the treatment of non-small cell lung cancer among older patients 3Health News:Model for breast cancer rehab featured in supplement to ACS journal, Cancer 2Health News:Opioids associated with highest risk of death 2Health News:MU receives national award for using mind-body approach to improve health 2Health News:Swallowing exercises linked with short-term improvement among patients with head and neck cancer 2Health News:Tattoos, Piercings Tied to Heavier Drinking in French Study 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: